DOYLESTOWN, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company…
LONG BEACH, Calif. and TORONTO, March 11, 2025 (GLOBE NEWSWIRE) -- Glass House Brands Inc. ("Glass House" or the "Company")…
Enhanced assay granted approval by New York State’s Clinical Lab Evaluation Program (CLEP) for patients with DLBCL clonoSEQ is the…
Additional Phase 2 data for vilastobart, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in patients with MSS CRC anticipated…
Announces Fiscal Year 2025 Non-GAAP Diluted EPS of Approximately $4.50 SAN DIEGO, March 10, 2025 /PRNewswire/ -- Illumina, Inc. (Nasdaq:…
Revolutionizing Law Enforcement, Medical and Military Applications STUART, Fla., March 10, 2025 /PRNewswire/ -- Base Molecular Resonance™ Technologies (BMRT), a…
MILAN and TEL HASHOMER, Israel, March 10, 2025 /PRNewswire/ -- Tethis S.p.A., a pioneer in standardized liquid biopsy platform development, and…
ALBANY, N.Y., March 07, 2025 (GLOBE NEWSWIRE) -- Curia Global, Inc. (Curia), a leading contract research, development and manufacturing organization,…
SOUTH SAN FRANCISCO, Calif., March 07, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company…
CAMBRIDGE, Mass., March 7, 2025 /PRNewswire/ -- Full Circles Therapeutics, a leader in next-generation genome engineering, announces that the United…